CBS 2019
CBSMD教育中心
English

推荐文献

科研文章

荐读文献

PCI and CABG for Treating Stable Coronary Artery Disease Timing and Causes of Unplanned Readmissions After Percutaneous Coronary Intervention: Insights From the Nationwide Readmission Database Select Drug-Drug Interactions With Direct Oral Anticoagulants Impact of Statins on Cardiovascular Outcomes Following Coronary Artery Calcium Scoring Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease Randomized Comparison of Everolimus- and Zotarolimus-Eluting Coronary Stents With Biolimus-Eluting Stents in All-Comer Patients Post-Stroke Cardiovascular Complications and Neurogenic Cardiac Injury: JACC State-of-the-Art Review Use of High-Risk Coronary Atherosclerotic Plaque Detection for Risk Stratification of Patients With Stable Chest Pain: A Secondary Analysis of the PROMISE Randomized Clinical Trial Coronary Angiography after Cardiac Arrest without ST-Segment Elevation

Original ResearchVolume 75, Issue 11, March 2020

JOURNAL:J Am Coll Cardiol. Article Link

Contrast-Associated Acute Kidney Injury and Serious Adverse Outcomes Following Angiography

SD Weisbord, PM Palevsky, the PRESERVE Trial Investigators et al. Keywords: angiography; contrast-associated acute kidney injury; mediation; outcomes

ABSTRACT

 

BACKGROUND - Contrast-associated acute kidney injury (CA-AKI) associates with an increased relative risk for serious adverse outcomes. However, the magnitude of this risk and the incidence of clinically significant CA-AKI derived from analyses of large cohorts with prospective assessment of CA-AKI and subsequent outcomes are unknown.

 

OBJECTIVES  - This study sought to characterize the relative risk for and incidence of serious adverse outcomes following the development of CA-AKI and to explore whether CA-AKI mediates the association of pre-angiography estimated glomerular filtration rate with adverse outcomes.

 

METHODS - Among 4,418 participants in the PRESERVE (Prevention of Serious Adverse Outcomes Following Angiography) trial with comprehensive baseline and outcome data, we assessed whether CA-AKI was associated with the 90-day outcome comprising death, need for dialysis, or persistent impairment in kidney function. We calculated the incidence of clinically significant CA-AKI (i.e., proportion of patients who developed CA-AKI and the 90-day outcome) and examined whether CA-AKI was a mediator of the association of baseline kidney function with the 90-day outcome.

 

RESULTS - CA-AKI was associated with an increased relative risk for 90-day death, need for dialysis, or persistent kidney impairment (odds ratio: 3.93; 95% confidence interval: 2.82 to 5.49; p < 0.0001). The incidence of clinically significant CA-AKI was 1.2% (53 of 4,418 patients). CA-AKI was not a mediator of the association of pre-angiography estimated glomerular filtration rate with the primary outcome.

 

CONCLUSIONS - CA-AKI was associated with an increased relative risk for 90-day death, need for dialysis, or persistent kidney impairment (odds ratio: 3.93; 95% confidence interval: 2.82 to 5.49; p < 0.0001). The incidence of clinically significant CA-AKI was 1.2% (53 of 4,418 patients). CA-AKI was not a mediator of the association of pre-angiography estimated glomerular filtration rate with the primary outcome.